Antiangiogenic Activity of the MDM2 Antagonist Nutlin-3 | Circulation Research
Oridonin synergizes with Nutlin-3 in inhibition of cell viability of OS... | Download Scientific Diagram
Idasanutlin (RG-7388) | ≥99%(HPLC) | Selleck | Mdm2 inhibitor
Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin- 3 in acute myeloid leukemia | Leukemia
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy | PNAS
Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53
Nutlin-3 upregulates noxa and induces apoptosis. (a and b)... | Download Scientific Diagram
Antiangiogenic Activity of the MDM2 Antagonist Nutlin-3 | Circulation Research
MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation | PLOS ONE
Nutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced cytotoxicity
Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer. - Abstract - Europe PMC
Frontiers | Clinical Overview of MDM2/X-Targeted Therapies | Oncology
The MDM2 ligand Nutlin-3 differentially alters expression of the immune blockade receptors PD-L1 and CD276 | Cellular & Molecular Biology Letters | Full Text
Targeted nutlin-3a loaded nanoparticles inhibiting p53–MDM2 interaction: novel strategy for breast cancer therapy | Nanomedicine
p53 programmes plough on
The hydrophobically-tagged MDM2–p53 interaction inhibitor Nutlin-3a-HT is more potent against tumor cells than Nutlin-3a - Chemical Communications (RSC Publishing) DOI:10.1039/C9CC07795B
Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment | Bentham Science
Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells | Cell Death & Disease
Extended treatment with Nutlin-3 results in reduced sensitivity without... | Download Scientific Diagram
Targeted nutlin-3a loaded nanoparticles inhibiting p53–MDM2 interaction: novel strategy for breast cancer therapy | Nanomedicine
Structurally diverse MDM2–p53 antagonists act as modulators of MDR-1 function in neuroblastoma | British Journal of Cancer
Cancers | Free Full-Text | Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists | HTML
Frontiers | Restoring p53 Function in Head and Neck Squamous Cell Carcinoma to Improve Treatments | Oncology
The MDM2 ligand Nutlin-3 differentially alters expression of the immune blockade receptors PD-L1 and CD276 | Cellular & Molecular Biology Letters | Full Text
